Prodotti competitors / Area Onco-Ema
Tapotoclax (AMG 176) with Azacitidine Phase I trial in Subjects with Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
AMG 176 (Tapotoclax) is an orally bioavailable, highly potent and selective Mcl-1 inhibitor, binding reversibly to BH3- groove of the protein with a Ki value in picomolar range.
Demonstrate in vitro and in vivo antitumor efficacy in Mcl-1 dependent cancer models. It is currently in clinical evaluation for the treatment of hematologic malignancies.
On Nov 28th, 2022, Amgen updated its P1 study of AMG-176 (MCL-1 inhibitor) + AZA in 1L HR-MDS and HMA-refractory MDS:
Study status: to “Recruiting” (from “Not yet recruiting”)
- 1 US-based trial site was added
- The enrollment number remains as 120 participants
Grazie per il tuo feedback!